Carcinoid tumors outside the abdomen by Kenna Koehler, Wade T. Iams

Get full text

Front Line Applications and Future Directions of Immunotherapy in Small-Cell Lung Cancer by Selina K. Wong, Wade T. Iams

Get full text

De Novo KRAS G12C–Mutant SCLC: A Case Report by Meridith L. Balbach, BS, Rosana Eisenberg, MD, Wade T. Iams, MD

Get full text

Successful Treatment and Retreatment With Erdafitinib for a Patient With FGFR3-TACC3 Fusion Squamous NSCLC: A Case Report by Chi Pham, BSc, Daenielle Lang, MD, Wade T. Iams, MD, MSCI

Get full text

Author Reply: In Response to “De Novo KRAS G12C-Mutant SCLC: A Case Report” by Meridith L. Balbach, BS, Rosana Eisenberg, MD, Wade T. Iams, MD, MSCI

Get full text

Two Uncomplicated Pregnancies on Alectinib in a Woman With Metastatic ALK-Rearranged NSCLC: A Case Report by Chloe Weidenbaum, DO, Christopher G. Cann, MD, Sarah Osmundson, MD, MS, Wade T. Iams, MD, MSCI, Travis Osterman, DO, MS

Get full text

692 COMMANDER-001: safety data from a phase I/II dose escalation/expansion study of SQZ-eAPC-HPV, a cell-based mRNA therapeutic cancer vaccine for HPV16+ solid tumors by Antonio Jimeno, Michael S Gordon, Howard Bernstein, Scott Loughhead, Jong Chul Park, Justin C Moser, Wade T Iams, Meredith Pelster, Kerry J Rodabaugh, Julia Jennings, Nathan Miselis, Marshelle S Warren, Victoria Villaflor, Melinda Morrison

594 SQZ-PBMC-HPV-101: Increased overall survival in a subset of patients with recurrent, locally advanced, or metastatic HPV16+ tumors treated with cell-based vaccine, SQZ-PBMC-HPV... by Neesha Dhani, Antonio Jimeno, Michael S Gordon, Matthew H Taylor, Howard Bernstein, Scott Loughhead, Joaquina Baranda, Udo Holtick, Jong Chul Park, Wade T Iams, Monica MitaSc, Kerry J Rodabaugh, E Amanda Duvall, Julia Jennings, Nathan Miselis, Marshelle S Warren

595 Biomarker results from the 1st line non-small cell lung cancer cohort of TACTI-002: pharmacodynamic effects of combining eftilagimod alpha (soluble LAG-3) and pembrolizumab by Enriqueta Felip, Christian Mueller, Martin Forster, Tim Clay, Matthew Krebs, Frederic Triebel, Enric Carcereny, Ewa Kalinka, Margarita Majem, Bernard Doger, Julio Peguero, Chrystelle Brignone, Igor Bondarenko, Wade T Iams, Manuel Cobo Dols, Grygorii Ursol, Gema Garcia Ledo, Laia Vilà Martinez

748 Phase 1/2 study of the hexavalent OX40 agonist INBRX-106 alone and in combination with pembrolizumab in select solid tumors by Daniel Olson, Manish Sharma, Erminia Massarelli, Jonathan Thompson, Rachel E Sanborn, Ralph J Hauke, Anthony W Tolcher, Elizabeth Davis, Conor Steuer, Muhammad Furqan, John Hamm, Doug Laux, David Berz, Wade T Iams, Vasily Andrianov, Brianne O’Neill, Yaiza Diaz De Durana

Making National Cancer Institute–Designated Comprehensive Cancer Center Knowledge Accessible to Community Oncologists via an Online Tumor Board: Longitudinal Observational Study by Maitri Kalra, Elizabeth Henry, Kelly McCann, Meghan S Karuturi, Jean G Bustamante Alvarez, Amanda Parkes, Robert Wesolowski, Mei Wei, Sarah S Mougalian, Gregory Durm, Angel Qin, Caitlin Schonewolf, Meghna Trivedi, Avan J Armaghani, Frederick H Wilson, Wade T Iams, Anita A Turk, Praveen Vikas, Michael Cecchini, Sam Lubner, Priyadarshini Pathak, Kristen Spencer, Vadim S Koshkin, Matthew K Labriola, Catherine H Marshall, Katy E Beckermann, Marina N Sharifi, Anthony C Bejjani, Varsha Hotchandani, Samir Housri, Nadine Housri

Get full text

The Efficacy and Safety of Treating Acquired MET Resistance Through Combinations of Parent and MET Tyrosine Kinase Inhibitors in Patients With Metastatic Oncogene-Driven NSCLC by Tejas Patil, MD, Alyse Staley, MS, Yunan Nie, MD, Mandy Sakamoto, MD, Margaret Stalker, MD, James M. Jurica, MD, MBA, Kenna Koehler, BA, Amanda Cass, PharmD, Halle Kuykendall, BA, Emily Schmitt, MS, Emma Filar, BA, Evelina Reventaite, MS, Kurt D. Davies, PhD, Hala Nijmeh, PhD, Mary Haag, PhD, Benjamin A. Yoder, PharmD, Paul A. Bunn, MD, Erin L. Schenk, MD, PhD, Dara L. Aisner, MD, PhD, Wade T. Iams, MD, Melina E. Marmarelis, MD, D. Ross Camidge, MD, PhD

Get full text